arrow
J

James A. Fagin

Memorial Sloan Kettering Cancer Center
H指数:93
被引数:3.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity ofBRAF-mutant anaplastic thyroid cancers

肿瘤细胞MHC II类分子的缺失驱动BRAF突变型间变性甲状腺癌对MAPK抑制剂的耐药性

2025-10-150
OA
Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement

放射性碘难治性不可切除或转移性甲状腺癌的再分化疗法:国际甲状腺肿瘤研究组声明

2025-04-300
OAAI
RAS-Mutated Cytologically Indeterminate Thyroid Nodules: Prevalence of Malignancy and Behavior Under Active Surveillance

RAS突变的细胞学不确定的甲状腺结节: 积极监测下的恶性肿瘤和行为的患病率

THYROID
IF6.7
2024-03-284
PRE
Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study

一项国际多中心研究中甲状腺髓样癌基因组谱与肿瘤特征和临床结局的关系

THYROID
IF6.7
2024-02-0119
OA
Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs

在核肿瘤学的日常临床实践中实现放射性药物治疗的个体化剂量: 克服对肿瘤和关键器官的辐射吸收剂量的异质性

2023-09-152
OAAI
The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients
2023-05-122
OAAI
Active Surveillance of Papillary Thyroid Cancer: Frequency and Time Course of the Six Most Common Tumor Volume Kinetic Patterns
THYROID
IF6.7
2022-11-0138
OA